The aromatic amines 2,4-diaminotoluene (2,4-DAT) and 2,6-diaminotoluene (2,6-DAT) are structural isomers that have been extensively studied for their mutagenic and carcinogenic characteristics. Both compounds are rapidly absorbed after oral administration and are equally mutagenic in the Ames test; however 2,4-DAT is a potent hepatocarcinogen, whereas 2,6-DAT does not produce an increased incidence of tumors in rats or mice at similar doses. The Big Blue transgenic B6C3Fj mouse carries multiple copies of the lacl mutational target gene. Our studies were designed to determine whether the Big Blue system could be used to detect differences in the in vivo mutagenic activity between the carcinogen-noncarcinogen pair 2,4-DAT and 2,6-DAT and to determine whether the in vivo mutagenesis assay results correspond to the rodent carcinogen bioassay results. Male B6C3F1 transgenic mice were exposed to 2,4-DAT or 2,6-DAT at 0 or 1,000 ppm in the diet for 30 and 90 days or to dimethyinitrosamine as a positive control. Mutant frequencies were nearly identical for all three groups at 30 days, while at 90 days the mutant frequency for the hepatocarcinogen 2,4-DAT (12.1 ± 1.4x 10-5) was significantly higher (p<0.01) as compared to both age-matched (spontaneous) controls (5.7±2.9x10-5) and the 2,6-DAT-exposed group (5.7 ± 2.4x 10-5).
Introduction
Transgenic mouse mutagenesis assays mutagenic properties of deleterious agents represent a novel approach for assessing the through the use of a stable genomic intemutagenicity of various compounds. gration of the X shuttle vector (XLIZ), Before the availability of these assays, the which carries a lacI target gene and a lacZ mutagenic properties of chemicals were reporter gene (1, 2) . After treatment of mice often determined using only short term in with the agent in question, genomic DNA vitro tests. The Big Blue assay represents an is isolated from the target organ(s) and the opportunity to examine the in vivo XLIZ is recovered using in vitro phage This paper was developed from a poster that was presented at the 2nd International Conference on Environmental Mutagens in Human Populations held [20] [21] [22] [23] [24] [25] We examined the mutagenic response of the carcinogen-noncarcinogen pair 2,4-and 2,6-diaminotoluene (DAT) (Figure 1 ) in the liver DNA of Big Blue mice after 30 and 90 days of exposure. Both compounds are used extensively in the synthesis of toluene diisocyanates for the production of polyurethane foams and elastomers, and the annual production of both isomers exceeds 100 million pounds (3, 4) . The compounds are equally mutagenic in the Ames/Salmonella assay in the presence of S9 (5), and both are readily absorbed, metabolized, and excreted (6) . However, while the 2,4-DAT isomer was found to be a potent rodent hepatocarcinogen when administered at 100 and 200 ppm in the National Toxicology Program (NTP) bioassay (3), the 2,6-DAT isomer was not carcinogenic when administered at doses up to 100 ppm (4) .
The Big Blue system has not been evaluated using a wide variety of exposure routes. Most Big Blue studies reported to date have used short-term, high-dose gavage or intraperitoneal exposures (ip) with potent mutagens (7, 8) . The Big Blue assay has been shown to be sensitive to butadiene administered by inhalation for four weeks (9) , and there is one report in which the Big Blue assay was used in a subchronic feeding study of the potent carcinogen, 2-acetylaminofluorene (2-AAF) at 600 ppm (10) . Neither of the two DAT isomers examined in our study are extremely potent in vitro mutagens; therefore, a longer-term continuous feeding study was chosen both to increase the sensitivity of the assay and to more closely mimic the dosing regimens used in the standard NTP bioassay. We examined the lacI mutant frequencies induced after exposing male B6C3F1 mice to 2,4-DAT and 2,6-DAT in feed. The phage/bacteria complexes were then added to 35 ml of molten (470 C) top agar (NZY media containing 0.7% agarose) containing 1.5 mg/ml X-gal (Stratagene). The top agar was then poured onto 25 x 25 cm2 assay trays containing 250 ml NZY bottom agar and incubated overnight at 37°C. Serially diluted phage were again plated in triplicate on the second day to determine the number of pfu per sample. The number of pfu per tray was never allowed to exceed 20,000 to ensure the detection of faint blue mutant plaques, with 15,000 plaques per plate considered to be optimum. Mutant frequencies were calculated based on the extrapolation from the triplicate titer plates generated at the time of plating for mutants (day 2). (The number of viable phage were not determined by counting portions of the large plates.) Blue plaques, indicating the mutant (lacI+) phenotype, were scored visually using a light box and a red-cellophane transparency to enhance the color contrast of the mutant plaques. All mutant plaques were scored by two individuals. Mutant plaques were cored into individual tubes containing 0.5 ml SM buffer (5.8 g NaCl, 2.0 g MgSO4 [7 H20 ], 50 ml 1.0 M Tris-HCl, 5 ml 2% gelatin [w/v], made up to 1 liter and pH 7.5 prior to autoclaving) and stored at 4°C for future verification. All mutant plaques were verified by replating isolated phage on 100 mm2 plates in the presence of X-gal.
Materials and Methods

Results
Effect ofDosing Time
Two of the five positive control animals died during treatment,. apparently due to Environmental Health Perspectives * Vol 104, Supplement 3 * May 1996 DISTINCTION OF MUTAGENIC CARCINOGENS AND NONCARCINOGENS the toxic effects of DMN. All of the DATexposed mice survived the length of the study. The observed Mf in the livers of DMN-treated positive control mice was 31 x 10-5, which is similar to published values using the same treatment regimen (8) . Mutant frequencies for the untreated control mice at 10.0 and 5.65 x 10-5 at 30 and 90 days, respectively, were similar to those previously reported (13) (14) (15) . The increased mutant frequency observed in 2,4-DAT-treated animals was statistically significantly different (p < 0.01) from agematched controls after feeding the chemical for 90 days, but not following 30 days of chemical exposure (Figure 2A and B) . These data indicate a longer dosing regimen may be necessary to observe induced mutations in vivo following treatment with less potent carcinogens. This may be due to the cumulative effects of chemical exposure over a period of 90 days compared to 30 days, to a requirement of a longer time period necessary for the expression of the mutant phenotype in vivo, or a combination of these and other factors.
Effects of Chemical Treatment
The Mf (meanx 10-5± SD; n = 5) at 30 days for control, 2,4-DAT, and 2,6 DAT groups were 10.0 ± 1.9, 9.3 ± 1.4, and 8.7 ± 2.8, respectively (Figure 2A) . The Mf at 90 days were 5.7± 2.9, 12.1 ± 1.4, and 5.6 ± 2.4 for control, 2,4-DAT and 2,6-DAT animals, respectively ( Figure 2B ). Using a one-way analysis of variance with a least significant difference test, there was a significant difference (p <0.01) in the observed Mf at 90 days between 2,4-DAT treated animals as compared to either the control or the 2,6-DAT-treated animals. The observed increase in Mf at 90 days in the 2,4-DAT treatment group was 2.1-fold over the negative control group Mf at 90 days. As expected, the Mf calculated for the positive control DMN-treated animals was also found to be statistically significantly higher (3.12-fold over control) than all other groups at both time points.
Discussion
The mutagenic isomers 2,4-DAT and 2,6-DAT are of special interest because of their differing carcinogenic response in bioassays conducted by the NTP, even though they exhibit similar mutagenic potencies in Salmonella typhimurium (5, 6) . The rats or mice at similar doses. Thus, it was of interest to determine the in vivo mutagenic potential of these isomers in the Big Blue assay system. In order to parallel the NTP 2-year bioassays of 2,4-DAT and 2,6-DAT, we chose to expose the animals to these chemical via the diet. Most Big Blue studies to date have used short-term exposure periods, high-potency mutagens, and parenteral dosing regimens. We reasoned that a continuous exposure study would also be more relevant for comparison to NTP bioassay results. The dose chosen (1,000 ppm) corresponds to the highest nontoxic dose used in a 90-day subchronic study (3, 4) . The results of the present study demonstrate that 90 days was an appropriate minimum time period for detecting mutations induced by 2,4-DAT administered by feeding. Other investigators have used the dietary route of exposure in the Big Blue model successfully but with the much more potent mutagen, 2-AAF (10). They demonstrated a 3-fold increase in Mf over background after a 28-day subchronic exposure to 600 ppm 2-AAF. The carcinogen, 2,4-DAT, at 1,000 ppm increased the observed Mf in the liver approximately 2-fold over the Mf observed in the agematched control group after 90 days but not after 30 days. The Mf in liver of the 2,6-DAT treatment group also delivered in the diet at 1,000 ppm was not significantly, different from the age-matched control group after either 30 or 90 days of chemical exposure. In this study, the positive control mutagen DMN induced a 3-fold increase in the observed Mf in the liver as compared to the Mf in the age-matched control group (Figure 2 ). It would appear from these data that longer exposures to some mutagens may be required to produce a detectable mutagenic response in vivo.
This observation should be considered in the design of studies assessing the in vivo mutagenic activity of chemicals of weak or unknown mutagenicity, as well as in the critical evaluation of studies that report negative results following short-term chemical treatment.
In the present study, mutation frequencies were assessed after 30-and 90-day exposures to 2,4-DAT or 2,6-DAT. We demonstrate a 2-fold increase in Mf at the 90-day time point in the 2,4-DAT-treated animals that was significant (p < 0.01) as compared to either the untreated controls or the 2,6-DAT-treated animals. Both these chemicals are in vitro mutagens in the Ames/Salmonella assay, although only 2,4-DAT induces unscheduled DNA synthesis (16) . That 2,4-DAT but not 2,6-DAT was found to be mutagenic in vivo is interesting in light of previous studies conducted in this laboratory in which we demonstrated that 2,4-DAT but not 2,6-DAT induces hepatocellular proliferation (17) . We postulate that a cytoproliferative effect in target organs could produce an elevated Mf in Big Blue mice as a result of clonal expansion of chemically mutated cells. Cells carrying DNA damage from either 2,4-DAT or 2,6-DAT treatment would yield mutations if forced to replicate; however, hepatocellular proliferation is only induced by 2,4-DAT. The cytotoxicity and compensatory cell proliferation induced by 2,4-DAT treatment leads to mutation fixation during cell proliferation. Such damage effectively increases the mutation rate (mutants/cell/ generation) leading to the elevated mutant frequency (mutants/viable phage) observed in 2,4-DAT-exposed mice at 90 days ( Figure 2B ). Such a mechanism could also be involved in the promotion and progression stages of carcinogenesis (18) . After 90 days of dietary exposure to 2,4-DAT, the Mf was significantly elevated compared to control ( Figure 2B ). This may reflect a sustained proliferative stimulus that may clonally expand mutant cell populations. After a 30-day exposure period, the Mf in 2,4-DAT-treated animals was not elevated, suggesting that longer exposure/expression periods may be necessary to observe the in vivo mutagenic effects of chemicals, the effects of chemicals administered via dietary exposure, or both. The noncarcinogenic isomer 2,6-DAT did not increase the Mf in either the 30-or 90-day animals at a treatment dose identical to the 2,4-DAT treatment dose. Thus, 2,6-DAT may not cause an increase in DNA damage in mouse liver and may only show a mutagenic response in vitro. The proliferative effect has not been observed in 2,6-DAT-exposed animals (17) . It is conceivable that DNA damage may have been induced in the liver by exposure to both 2,4-DAT and 2,6-DAT. In the absence of cellular replication in the case of 2,6-DAT-treated mice, such damage may have been repaired with a corresponding reduction of the Mf to background levels. The only known difference between these two in vitro mutagens to explain their widely different mutagenic activity in vivo lies in the abiity of 2,4-DAT to induce hepatocellular proliferation. Chemically induced cell proliferation may therefore be a critical factor in fixation of mutations in vivo. Consistent with a view invoking differential DNA repair, it has been shown recently that enhanced repair of DNA adducts can prevent the carcinogenic effects of methylnitrosourea (19) .
In conclusion, this study demonstrates that the Big Blue assay is able to discriminate between the in vivo mutagenic response of two compounds with differing carcinogenic properties but with similar mutagenic activity in S. typhimurium. The major difference between these two chemicals in vivo is an induced cell proliferative response following exposure to 2,4-DAT that does not occur after treatment with 2,6-DAT, suggesting an important role for chemically induced cell proliferation on the mutagenic effect of chemicals. This study also illustrates that the dietary administration of chemicals is an appropriate route of administration for in vivo mutagenesis studies, allowing for longer duration exposures. We believe that these data help to validate this transgenic mouse model as a potential indicator of carcinogenic response and suggest that the Big Blue assay is also useful for mechanistic studies of carcinogenicity.
